ArticleKorean journal of pediatrics2014
Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines.
Article in Korean journal of pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Recommendation for use of 15- and 20-valent pneumococcal conjugate vaccines in Korean infants and children.Clinical and experimental pediatrics · 2026Guideline
- Effectiveness and impact of 7 and 13-valent pneumococcal conjugate vaccines in Chinese children: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2025Pooled it
- Safety and Immunogenicity of Pneumococcal Conjugate Vaccine in Preterm Infants: A Meta-Analysis.Indian journal of pediatrics · 2017Pooled it
- Review
- A Trivalent Live Vaccine Elicits Cross-Species Protection Against Acute Otitis Media in a Murine Model.Vaccines · 2024Article
- Progress in research and development of preventive vaccines for children in China.Frontiers in pediatrics · 2024Review
- The dilemma of improving rational antibiotic use in pediatric community-acquired pneumonia.Frontiers in pediatrics · 2023Review
- Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies.Frontiers in cellular and infection microbiology · 2022Review
- Non-capsular based immunization approaches to preventFrontiers in cellular and infection microbiology · 2022Review
- Prevalence and Antimicrobial Susceptibility ofBioMed research international · 2021Article
- Article
- Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly.Risk management and healthcare policy · 2018Review
- Pneumonia and Streptococcus pneumoniae vaccine.Archives of pharmacal research · 2017Review
- Observational
- Antibiotic Control Policies in South Korea, 2000-2013.Infection & chemotherapy · 2016Review
- Next generation protein based Streptococcus pneumoniae vaccines.Human vaccines & immunotherapeutics · 2016Review
- The prevention of pneumococcal infections.Clinical and experimental vaccine research · 2016Article
- The host immune dynamics of pneumococcal colonization: implications for novel vaccine development.Human vaccines & immunotherapeutics · 2014Review
- The dichotomy of pathogens and allergens in vaccination approaches.Frontiers in microbiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 7-valent pneumococcal protein conjugate vaccine (PCV7) has been shown to be highly efficacious against invasive pneumococcal diseases and effective against pneumonia and in reducing otitis media. The introduction of PCV7 has resulted in major changes in the epidemiology of pneumococcal diseases. However, pneumococcal vaccines induce serotype-specific immunity, and a relative increase in non-vaccine serotypes has been reported following the widespread use of PCV7, leading to a need for extended serotype coverage for protection. PCV10 and PCV13 have been licensed on the basis of noninferiority of immunogenicity compared to a licensed conjugate vaccine. In this article, we aimed to review important data regarding the efficacy and effectiveness of the extended-coverage PCVs published or reported thus far and to discuss future implications for pneumococcal vaccines in Korea. After the introduction of PCV10 and PCV13, within a short period of time, evidence of protection conferred by these vaccines against invasive and mucosal infections caused by most of the serotypes included in the vaccines is accumulating. The choice of vaccine should be based on the changes in the dynamics of pneumococcal serotype distribution and diseases in the region where the vaccines are to be used. Continuous surveillance is essential for the appropriate use of pneumococcal vaccines and evaluation of the impact of PCVs on pneumococcal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.